A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma

Clin Cancer Res. 2022 Dec 1;28(23):5010-5012. doi: 10.1158/1078-0432.CCR-22-2626.

Abstract

A microencapsulated, cell-based IL2 cytokine factory was recently developed, and the safety and efficacy of this platform in a mouse model of mesothelioma were demonstrated. This platform has the potential to overcome current challenges in the delivery of therapeutic cytokines for cancer immunotherapy. See related article by Nash et al., p. 5121.

Publication types

  • Editorial
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Animals
  • Cytokines / therapeutic use
  • Immunity, Innate
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / genetics
  • Mesothelioma* / drug therapy
  • Mesothelioma* / pathology
  • Mesothelioma, Malignant*
  • Mice

Substances

  • Cytokines
  • Interleukin-2